Well, for starters, we shouldn't name as part of the DSMB a person who has just led a large trial for Gilead's Remdeathisnear -- our competition, who would benefit to the tune of $20 billion by the disappearance of Leronlimab from the Covid indication. The company names the DSMB. Nader should have been able to figure out that he was not an optimal candidate.